Visconti and colleagues used FRTL-5 rat thyroid cells infected with Kirsten murine sarcoma virus carrying v-Ki-Ras as a model of complete thyroid transformation. Affymetrix oligonucleotide arrays interrogating ~17,000 rat sequences identified ~1,000 genes changed twofold; applying an arbitrary tenfold filter narrowed this to ~50 upregulated and ~40 downregulated genes. All thyroid differentiation markers (thyroglobulin, TSH receptor) were severely repressed, and Ki-Ras itself was upregulated, serving as an internal positive control .
RT-PCR confirmed direction (not exact magnitude) of all tested genes in FRTL-5 v-Ki-Ras. RalA was induced in PC Cl3 v-mos and v-raf lines (but not E1A alone), suggesting Raf-dependent regulation. In seven human thyroid carcinoma lines (WRO, FB-2, NPA, TPC-1, B-CPAP, FRO, ARO), Annexin A2 and RalA were upregulated in all seven; CD24 and Dusp1 were downregulated in all; CD24 was undetectable in 4/7 lines and strongly repressed in all anaplastic tumor samples .
The CD24 result contradicts most cancer literature, where high CD24 correlates with aggressive epithelial cancers (ovarian, breast, lung, prostate, pancreatic) . The interferon-inducible gene downregulated by Ras in rat cells was also repressed in fibroblast and ovarian Ras-transformation datasets, but human tumor confirmation was only preliminary. Notably, only 6 of ~100 Ras-modulated genes overlapped with prior Ras-transcriptome studies in mast cells and fibroblasts, suggesting thyroid-specific regulation .
Confidence note: The central transcriptional findings are internally consistent (RT-PCR concordance across rat, human lines, and tumors), but the strength of the evidence rests on semiquantitative PCR rather than quantitative methods, and the absence of replicates/public data weakens reproducibility. What would change this assessment: independent replication in Ras-mutant human thyroid cohorts with RNA-seq, and functional tests of candidate genes in transformation assays.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.